Evaluating functional electrical stimulation (FES) cycling on cardiovascular, musculoskeletal and functional outcomes in adults with multiple sclerosis and mobility impairment: A systematic review

Scally, Jennifer; Baker, Julien S.; Rankin, Jean; Renfrew, Linda Miller; Sculthorpe, Nicholas

doi:10.1016/j.msard.2019.101485

Cited by 13 publications

(8 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35 Notably, similar to earlier studies, there were no adverse events associated with FES cycle training in this study, and no increase in MS-related spasticity, fatigue, or pain. 18,19 Similar to earlier studies of FES cycling in people with MS who primarily use a wheelchair for mobility, 10,13,15 most participants in the training group (four of six) improved in their FES cycling performance, suggesting that they have the capacity for change in neuromuscular conditioning and control.…”

Section: Discussionsupporting

confidence: 72%

“…Scally et al 19 and Edwards and Pilutti 20 also highlighted the need for randomized controlled trials evaluating the efficacy of FES cycling in people with severe disability. Given that MS is a chronic and progressive condition, a lack of decline in function or no increase in symptoms can be meaningful.…”

Section: Fes Cycle Training Interventionmentioning

confidence: 99%

“…However, emerging evidence suggests that people with greater levels of disability, including those who use a wheelchair as their primary means of mobility, can safely exercise and, furthermore, may also benefit from increasing their activity. [8][9][10][11][12][13][14][15][16][17][18][19][20][21] A major challenge for people who use wheelchairs is the barrier to exercise options. 22,23 Weakness, paralysis, spasticity, and fatigue often make it difficult to exercise at an intensity or duration that provides a sufficient exer-cise stimulus.…”

mentioning

confidence: 99%

“…This intervention combines the use of surface electrical stimulation with a motor-powered ergometer and is a potential exercise option for people with MS who are nonambulatory (Expanded Disability Status Scale [EDSS] score >6.5). 9,11,13,15,19,21 Two recent reviews report the potential of FES cycling for reducing symptoms and improving the quality of life (QOL) for people with MS who have substantial mobility impairment. 19,20 However, both reports highlight the heterogeneity of participants in earlier studies (ie, including both those with MS who are ambulatory and nonambulatory), making it difficult to determine the specific effect on people with MS who are nonambulatory.…”

mentioning

confidence: 99%

“…9,11,13,15,19,21 Two recent reviews report the potential of FES cycling for reducing symptoms and improving the quality of life (QOL) for people with MS who have substantial mobility impairment. 19,20 However, both reports highlight the heterogeneity of participants in earlier studies (ie, including both those with MS who are ambulatory and nonambulatory), making it difficult to determine the specific effect on people with MS who are nonambulatory. Backus et al 13,15 reported that 14 people with MS, all of whom could not ambulate in the community and used a wheelchair for mobility, who took part in FES cycle training two to three times a week for 4 to 5 weeks (12 sessions total) not only did so without adverse events but also improved their cycling performance.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Effects of Functional Electrical Stimulation Cycling on Fatigue and Quality of Life in People with Multiple Sclerosis Who Are Nonambulatory

Backus¹,

Moldavskiy²,

Sweatman³

2020

International Journal of MS Care

View full text Add to dashboard Cite

CME/CNE Information Activity Available Online: To access the article, post-test, and evaluation online, go to http://www.cmscscholar.org. Target Audience: The target audience for this activity is physicians, physician assistants, nursing professionals, rehabilitation professionals, and other health care providers involved in the management of patients with multiple sclerosis (MS). Learning Objectives: 1) Discuss the rationale for functional electrical stimulation (FES) cycling for people with MS who are nonambulatory and use a wheelchair for mobility. 2) Describe an FES protocol that is safe and potentially effective for people with MS who are nonambulatory. Accreditation Statement: In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Delaware Media Group. The CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Physician Credit: The CMSC designates this journal-based activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse Credit: The CMSC designates this enduring material for 1.0 contact hour (none in the area of pharmacology). Disclosures: Francois Bethoux, MD, Editor in Chief of the International Journal of MS Care (IJMSC), has served as Physician Planner for this activity. He has disclosed relationships with Springer Publishing (royalty), Qr8 (receipt of intellectual property rights/patent holder), Biogen (receipt of intellectual property rights/patent holder, speakers’ bureau), GW Pharma (consulting fee), MedRhythms (consulting fee, contracted research), and Adamas Pharmaceuticals (contracted research). Laurie Scudder, DNP, NP, has served as Reviewer for this activity. She has disclosed no relevant financial relationships. Deborah Backus, PT, PhD, has disclosed no relevant financial relationships. Marina Moldavskiy, BS, has disclosed no relevant financial relationships. W. Mark Sweatman, PhD, MBA, has disclosed no relevant financial relationships. The peer reviewers for IJMSC have disclosed no relevant financial relationships. The staff at IJMSC, CMSC, and Delaware Media Group who are in a position to influence content have disclosed no relevant financial relationships. Note: Financial relationships may have changed in the interval between listing these disclosures and publication of the article. Method of Participation: Release Date: August 1, 2020 Valid for Credit Through: August 1, 2021 In order to receive CME/CNE credit, participants must: 1) Review the continuing education information, including learning objectives and author disclosures.2) Study the educational content.3) Complete the post-test and evaluation, which are available at http://www.cmscscholar.org Statements of Credit are awarded upon successful completion of the post-test with a passing score of >70% and the evaluation. There is no fee to participate in this activity. Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA. The CMSC and Delaware Media Group do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the CMSC or Delaware Media Group. Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any medications, diagnostic procedures, or treatments discussed in this publication should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

show abstract